Last reviewed · How we verify
Ciclesonide nasal spray + placebo Azelastine
Ciclesonide is an intranasal corticosteroid that reduces airway inflammation and mucus production to relieve nasal allergy symptoms.
Ciclesonide is an intranasal corticosteroid that reduces airway inflammation and mucus production to relieve nasal allergy symptoms. Used for Allergic rhinitis (seasonal and perennial).
At a glance
| Generic name | Ciclesonide nasal spray + placebo Azelastine |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Intranasal corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | FDA-approved |
Mechanism of action
Ciclesonide is a prodrug that is converted to its active metabolite in the nasal mucosa, where it binds to glucocorticoid receptors and suppresses inflammatory cytokine production, reducing nasal congestion, rhinorrhea, and sneezing associated with allergic rhinitis. This formulation combines ciclesonide nasal spray with placebo azelastine (a histamine H1-receptor antagonist), allowing evaluation of ciclesonide monotherapy efficacy.
Approved indications
- Allergic rhinitis (seasonal and perennial)
Common side effects
- Headache
- Epistaxis (nosebleed)
- Nasal irritation
- Pharyngitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: